Literature DB >> 10178645

Pharmacoeconomics in the new millennium. A pharmaceutical industry perspective.

R Thwaites1, R J Townsend.   

Abstract

The primary purpose of pharmacoeconomic research is to assist in making healthcare decisions. Rapid growth in the supply of pharmacoeconomic data over the past few years suggests that pharmacoeconomics can be of help in delivering good, cost-effective healthcare. Greater challenges in decision-making coupled with improvements in the techniques of pharmacoeconomic research point to a greater role for pharmacoeconomics into the new millennium. This in turn will have consequences for companies in the pharmaceutical industry. More successful access to markets and better commercialisation of products will be the rewards for those companies committing to pharmacoeconomics and to the broader goal of delivering value for money in healthcare.

Mesh:

Year:  1998        PMID: 10178645     DOI: 10.2165/00019053-199813020-00002

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  5 in total

1.  The Danish approach to standards for economic evaluation methodologies.

Authors:  A Alban; M Gyldmark; A V Pedersen; J Søgaard
Journal:  Pharmacoeconomics       Date:  1997-12       Impact factor: 4.981

2.  Economic evaluations of drug therapy: attitudes of primary care prescribing advisers in Great Britain.

Authors:  T Walley; S Barton; J Cooke; M Drummond
Journal:  Health Policy       Date:  1997-07       Impact factor: 2.980

3.  Methodological and conduct principles for pharmacoeconomic research. Pharmaceutical Research and Manufacturers of America.

Authors:  K Clemens; R Townsend; F Luscombe; J Mauskopf; J Osterhaus; J Bobula
Journal:  Pharmacoeconomics       Date:  1995-08       Impact factor: 4.981

4.  A proposal for Italian guidelines in pharmacoeconomics The Mario Negri Institute Centre for Health Economics.

Authors:  L Garattini; R Grilli; D Scopelliti; L Mantovani
Journal:  Pharmacoeconomics       Date:  1995-01       Impact factor: 4.981

Review 5.  Quality of life and clinical trials.

Authors: 
Journal:  Lancet       Date:  1995-07-01       Impact factor: 79.321

  5 in total
  4 in total

1.  Pharmacoeconomics and health policy. Current applications and prospects for the future.

Authors:  P E Greenberg; A Arcelus; H G Birnbaum; P Y Cremieux; J LeLorier; P Ouellette; M B Slavin
Journal:  Pharmacoeconomics       Date:  1999-11       Impact factor: 4.981

2.  Using health outcomes data to inform decision-making: a pharmaceutical industry perspective.

Authors:  M Keech
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

3.  Pharmacy benefit management: enhancing the applicability of pharmacoeconomics for optimal decision making.

Authors:  C Daniel Mullins; Junling Wang
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

4.  Emerging role of pharmacoeconomics in the research and development decision-making process.

Authors:  J A DiMasi; E Caglarcan; M Wood-Armany
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.